Carfilzomib weekly 20/56mg/m2, lenalidomide and dexamethasone for early relapsed refractory multiple myeloma.

被引：0
|
作者：
Richez, Valentine
Guidez, Stephanie
Azais, Isabelle
Durand, Geraldine
Javaugue, Vincent
Brigaud, Antoine
Machet, Antoine
Moya, Niels
Gruchet, Cecile
Bobin, Arthur
Levy, Anthony
Sabirou, Florence
Dieval, Celine
Fleck, Emmanuel
Princet, Isabelle
Bauwens, Delphine
Fouquet, Guillemette
Bridoux, Frank
Avet-Loiseau, Herve
Leleu, Xavier
机构：
[1] Univ Nice Sophia Antipolis, Nice, France
[2] Univ Poitiers Hosp, INSERM, CIC 1402, Poitiers, France
[3] Univ Poitiers Hosp, Poitiers, France
[4] Angouleme Hosp, Angouleme, France
[5] Poitiers Hosp, Poitiers, France
[6] Rochefort Hosp, Rochefort, France
[7] LaRochelle Hosp, Rochelle, France
[8] CHR LA MILETRIE, Poitiers, France
[9] CHRU Lille, Hematology, Lille, France
[10] Toulouse Inst Natl Sante, Univ Canc Ctr, Toulouse, France
[11] CHU Poitiers, Poitiers, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.8017
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8017
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Carfilzomib Weekly 20/56mg/m2, Lenalidomide and Dexamethasone for Early Relapsed Refractory Multiple Myeloma
    Valentine, Richez
    Guidez, Stephanie
    Azais, Isabelle
    Durand, Geraldine
    Javaugue, Vincent
    Brigaud, Antoine
    Plasse, Florent
    Diolez, Jeremie
    Machet, Antoine
    Moya, Niels
    Gruchet, Cecile
    Bobin, Arthur
    Levy, Anthony
    Sabirou, Florence
    Bonnin, Anthony
    Dieval, Celine
    Primault, Sylvain
    Barrier, Jocelyn
    Fleck, Emmanuel
    Daras, Claire
    Princet, Isabelle
    Bauwens, Delphine
    Fouquet, Guillemette
    Bridoux, Frank
    Loiseau, Herve Avet
    Leleu, Xavier
    BLOOD, 2017, 130
  • [2] Weekly 20/56mg/m2 Carfilzomib, Lenalidomide and Dexamethasone until progression in Early Relapsed Refractory Multiple Myeloma
    Gruchet, Cecile
    Richez, Valentine
    Guidez, Stephanie
    Sabirou, Florence
    Moya, Niels
    Levy, Anthony
    Bobin, Arthur
    Gardeney, Helene
    Nsiala, Laly
    Machet, Antoine
    Fouquet, Guillemette
    Azais, Isabelle
    Durand, Geraldine
    Avet-Loiseau, Herve
    Leleu, Xavier
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E258 - E258
  • [3] Weekly 20/56 mg/m2 carfilzomib, lenalidomide, and dexamethasone until progression in early relapsed refractory multiple myeloma.
    Gruchet, Cecile
    Richez, Valentine
    Guidez, Stephanie
    Fouquet, Guillemette
    Azais, Isabelle
    Durand, Geraldine
    Javaugue, Vincent
    Plasse, Florent
    Machet, Antoine
    Moya, Niels
    Gardeney, Helene
    Bobin, Arthur
    Levy, Anthony
    Sabirou, Florence
    Bonnin, Anthony
    Dieval, Celine
    Primault, Sylvain
    Bridoux, Frank
    Avet-Loiseau, Herve
    Leleu, Xavier
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [4] Carfilzomib weekly 20/56 mg/m2, lenalidomide and dexamethasone for early relapsed refractory multiple myeloma
    Richez, Valentine
    Gruchet, Cecile
    Guidez, Stephanie
    Fouquet, Guillemette
    Azais, Isabelle
    Durand, Geraldine
    Javaugue, Vincent
    Brigaud, Antoine
    Plasse, Florent
    Diolez, Jeremie
    Machet, Antoine
    Moya, Niels
    Gardeney, Helene
    Franques, Paul
    Bobin, Arthur
    Levy, Anthony
    Sabirou, Florence
    Bonnin, Anthony
    Dieval, Celine
    Primault, Sylvain
    Barrier, Jocelyn
    Fleck, Emmanuel
    Bouyier, Sabrina
    Daras, Claire
    Princet, Isabelle
    Bauwens, Delphine
    Legros, Laurence
    Fuzibet, Jean-Gabriel
    Gil, Angela
    Bridoux, Frank
    Avet-Loiseau, Herve
    Leleu, Xavier
    AMERICAN JOURNAL OF HEMATOLOGY, 2019, 94 (01) : E17 - E20
  • [5] Carfilzomib-lenalidomide-dexamethasone in the management of lenalidomide-refractory multiple myeloma.
    Cerchione, Claudio
    Martinelli, Giovanni
    Nappi, Davide
    Pareto, Anna Emanuele
    Di Perna, Maria
    Ferrara, Katia
    Pane, Fabrizio
    Catalano, Lucio
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [6] Once-weekly (70 mg/m2) versus twice weekly (56 mg/m2) dosing of carfilzomib (CFZ) for patients (pts) with relapsed and/or refractory multiple myeloma (RRMM).
    Moreau, Philippe
    Stewart, A. Keith
    Dimopoulos, Meletios A.
    Siegel, David Samuel DiCapua
    Facon, Thierry
    Berenson, James R.
    Raje, Noopur S.
    Berdeja, Jesus G.
    Orlowski, Robert Z.
    Yang, Hui
    Ma, Haijun
    Karina Klippel, Zandra
    Zahlten-Kumeli, Anita
    Mezzi, Khalid
    Iskander, Karim
    Mateos, Maria-Victoria
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [7] A phase II study of daratumumab with weekly carfilzomib, pomalidomide, and dexamethasone in relapsed and refractory multiple myeloma.
    Yee, Andrew J.
    Nadeem, Omar
    Rosenblatt, Jacalyn
    Bianchi, Giada
    O'Donnell, Elizabeth
    Branagan, Andrew R.
    Harrington, Cynthia C.
    Agyemang, Emerentia A.
    Gammon, Marilyn T.
    Lively, Kathleen J.
    Packer, Lisette A.
    Bernstein, Zachary S.
    Lyons, Rebecca T.
    Riadi, Manal
    Rowell, Sean M.
    Mcvey, Cailin
    Goguen, Amy C.
    Horick, Nora K.
    Richardson, Paul G.
    Raje, Noopur S.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [8] Randomized phase II study of weekly carfilzomib 70 mg/m2 and dexamethasone with or without cyclophosphamide in relapsed and/or refractory multiple myeloma patients
    Puertas, Borja
    Gonzalez-Calle, Veronica
    Sureda, Anna
    Moreno, Maria Jose
    Oriol, Albert
    Gonzalez, Esther
    Rosinol, Laura
    Lopez, Jordi
    Escalante, Fernando
    Martinez-Lopez, Joaquin
    Carrillo, Estrella
    Clavero, Esther
    Rios-Tamayo, Rafael
    Rey-Bua, Beatriz
    Gonzalez-Rodriguez, Ana Pilar
    Dourdil, Victoria
    de Arriba, Felipe
    Gonzalez, Sonia
    Perez-de-Oteyza, Jaime
    Hernandez, Miguel T.
    Garcia-Mateo, Aranzazu
    Bargay, Joan
    Blade, Joan
    Lahuerta, Juan Jose
    San Miguel, Jesus F.
    Ocio, Enrique M.
    Mateos, Maria-Victoria
    HAEMATOLOGICA, 2023, 108 (10) : 2753 - 2763
  • [9] CARFILZOMIB, LENALIDOMIDE AND DEXAMETHASONE IN JAPANESE PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA
    Ri, M.
    Suzuki, K.
    Chou, T.
    Sugiura, I.
    Takezako, N.
    Sunami, K.
    Ishida, T.
    Izumi, T.
    Ozaki, S.
    Iida, S.
    HAEMATOLOGICA, 2016, 101 : 787 - 788
  • [10] Weekly carfilzomib, lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: A phase 1b study
    Biran, Noa
    Siegel, David
    Berdeja, Jesus G.
    Raje, Noopur
    Cornell, Robert Frank
    Alsina, Melissa
    Kovacsovics, Tibor
    Fang, Belle
    Kimball, Amy S.
    Landgren, Ola
    AMERICAN JOURNAL OF HEMATOLOGY, 2019, 94 (07) : 794 - 802
12345